Curated News
By: NewsRamp Editorial Staff
July 28, 2025
Lantern Pharma Appoints Oncology Expert to Board, Boosting AI-Driven Cancer Research
TLDR
- Lantern Pharma's appointment of Dr. Lee T. Schalop enhances its competitive edge in AI-driven oncology drug discovery, leveraging his expertise in neurooncology and strategic transactions.
- Lantern Pharma utilizes its RADR platform, analyzing over 200 billion oncology data points with 200+ ML algorithms, to streamline drug development from AI insights to clinical trials in 2-3 years.
- Lantern Pharma's AI-powered approach accelerates the development of novel therapies, offering hope to patients with limited treatment options and advancing the fight against cancer.
- Discover how Lantern Pharma's AI and Dr. Schalop's neurooncology expertise could revolutionize cancer treatment, turning data into life-saving therapies faster than ever before.
Impact - Why it Matters
This development is crucial as it highlights the intersection of artificial intelligence and healthcare, specifically in the fight against cancer. Lantern Pharma's innovative use of AI to streamline drug discovery and development could lead to faster, more cost-effective treatments for patients with limited options. The appointment of Dr. Schalop, with his extensive experience in biotechnology and strategic transactions, signals a strong future for the company's oncology programs, potentially bringing hope to millions affected by cancer worldwide.
Summary
Lantern Pharma (NASDAQ: LTRN), a pioneer in using artificial intelligence and genomic data for oncology drug discovery, has strengthened its leadership by appointing Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop, renowned for his role in the development of targeted therapies for solid tumors and his leadership at Oncoceutics Inc., brings invaluable expertise to Lantern Pharma. His appointment is expected to accelerate the company's precision oncology programs, particularly in CNS cancer treatments through its subsidiary, Starlight Therapeutics. Lantern Pharma's innovative approach, powered by its RADR(R) AI platform, has significantly reduced the time and cost of bringing new cancer therapies to clinical trials, showcasing the transformative potential of AI in drug development.
For more details, visit the full press release at https://ibn.fm/bDXDZ. Lantern Pharma's commitment to revolutionizing cancer treatment through AI and machine learning is further highlighted by its rapid advancement of drug programs from AI insights to clinical trials in just 2-3 years, at a fraction of the traditional cost. This news underscores the growing importance of AI in healthcare and the potential for significant breakthroughs in oncology.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Appoints Oncology Expert to Board, Boosting AI-Driven Cancer Research
